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BACKGROUND: Dyskerin encoded by the DKC1 gene is a predominantly nucleolar protein essential for the formation of pseudouridine
in RNA and the telomerase RNA subunit hTR. Inherited mutations inactivating dyskerin cause dyskeratosis congenita, a syndrome
with progeroid features characterised by skin defects and haematopoiesis failure, as well as cancer susceptibility. In this study, we
report DKC1 overexpression in prostate cancers.
METHODS: Expression of DKC1 was measured by quantitative RT–PCR in prostate cancer tissues in relation to hTR and the
proliferation marker MKI67. Effects of dyskerin downregulation on proliferation, apoptosis and senescence of prostate cancer cell
lines were determined.
RESULTS: DKC1 was significantly overexpressed in prostate cancers, particularly in high-stage and recurring cases, correlating
moderately with hTR and MKI67. Dyskerin downregulation in prostate carcinoma cell lines by siRNA diminished cell proliferation, but
elicited neither apoptosis nor senescence. Apoptosis induction by TNF-a or tunicamycin was not enhanced. Long-term
downregulation led predominantly to cell shrinking and loss of adhesion.
INTERPRETATION: DKC1 upregulation in prostate cancers is common and likely to be necessary for extensive tumour growth. The
phenotype of prostate carcinoma cell lines after dyskerin downregulation suggests that its most critical function is sustaining protein
biosynthesis. Intriguingly, compromised function and overexpression of dyskerin can both contribute to cancer development.
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Dyskerin, also known as Cbf5, is a predominantly nucleolar
protein encoded by the DKC1 gene at Xq28 (Mason et al, 2005;
Kirwan and Dokal, 2008). As part of a snoRNA ribonucleoprotein
complex, dyskerin catalyses the formation of pseudouridine in
ribosomal and certain small RNAs (Filipowicz and Pogacic, 2002).
Moreover, dyskerin is necessary for the biogenesis of hTR, the
RNA component of telomerase, which is transcribed from the
TERC gene. The hTR RNA contains a specific recognition motif
for dyskerin, and dyskerin is retained in the core telomerase
complex (Chang et al, 2002; Cohen et al, 2007). Very recently,
dyskerin was reported to exert an additional function by regulating
the translation of a number of anti-apoptotic proteins (Yoon et al,
2006).
Inherited mutations in DKC1 cause the human hereditary
syndrome, dyskeratosis congenita (Mason et al, 2005; Kirwan and
Dokal, 2008). Owing to the localisation of DKC1 at Xq28, males
are predominantly affected, whereas females heterozygous for a
mutant gene seem to compensate by selection of cells with the
active functional allele. The symptoms of the disease are variable.
In most cases, dyskeratosis congenita manifests initially as defects
in reticulate skin pigmentation, nail dystrophy, and mucosal
leukoplakia. Progressively deficient haematopoiesis is the main
cause of death. Evidently, insufficient dyskerin function primarily
affects tissues with rapid cell turnover, such as the skin and the
haematopoietic system, likely as a consequence of impaired cell
proliferation. Somewhat paradoxically, dyskeratosis congenita
patients are also prone to develop cancers, particularly skin
cancers and leukaemias. Moreover, in sporadic chronic lympho-
cytic leukaemia, DKC1 expression is diminished, together with that
of other telomerase-associated factors (Poncet et al, 2008). It is
debated as to loss of which function of dyskerin is most crucial for
the symptoms of dyskeratosis congenita. Some experts argue that
insufficient protein synthesis resulting from defects in ribosome
biogenesis may compromise tissue regeneration, whereas others
emphasise that telomerase dysfunction caused by hTR deficiency
may limit the renewal of tissue stem cells (Mason et al, 2005; Wong
and Collins, 2006; Kirwan and Dokal, 2008). The latter argument is
supported by the observation that inherited mutations in TERC
elicit a similar, although generally milder form of the disease.
Perhaps because of the defects in stem cell function, dyskeratosis
congenita has some similarities to progeroid syndromes (Kirwan
and Dokal, 2008).
Although increased nucleolar activity is a long-established
indicator of malignancy (reviewed in Montanaro et al (2008b)),
dyskerin expression and function in sporadic cancers have hardly
been investigated. A pioneer study has reported dyskerin
expression to be increased in several human cancer types,
especially in breast cancers (Montanaro et al, 2006). In accord
with the known biological functions of the protein, breast cancers
with low dyskerin expression contained lower levels of pseudour-
idine and telomerase RNA than those with high expression.
Moreover, cancers with high expression generally exhibited worse
histopathological features and prognosis. In line with these
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sfindings, a microarray study from our group (Schulz et al, 2007)
indicated significantly increased DKC1 expression in a subset of
prostate cancers with a combination of molecular changes, that is,
chromosome 8 alterations and LINE-1 hypomethylation, typical of
advanced cases. This prompted us to investigate DKC1 expression
and dyskerin function in prostate cancer.
MATERIALS AND METHODS
Tissue samples
Prostate cancer specimens were obtained between 1997 and 2002
by radical prostatectomy as described (Schulz et al, 2007). TNM
classification was performed according to the guidelines of
the International Union Against Cancer from 1997. Of 47 prostate
carcinoma tissues used for molecular analyses, 20 carcinomas were
staged as pT2, 25 as pT3, and 2 as pT4. Lymph node metastases
were present in 12 patients. None of the patients had detectable
distant metastases at the time of surgery. Gleason sums of tumours
were p6 in 13 cases, 7 in 26 cases, and 47 in 8 cases. The mean
patient age was 67 years, ranging from 59 to 74 years. All patients
were followed up for a mean period of more than 5 years. During
this time, 13 patients suffered recurrences. The study was
approved by the ethics committee of the Heinrich Heine University
medical faculty.
Cell lines and cultivation
The prostate carcinoma cell lines, 22Rv1, LNCaP, PC3, and
Du145, were cultured in RPMI-1640 (Gibco Life Technologies,
Karlsruhe, Germany), supplemented with 10% foetal calf
serum (FCS) and 100Uml
–1 penicillin/100mgml
 1 streptomycin.
MDAPCa2b was cultured in F12K medium supplemented with 20%
FCS, 100mgml
 1 penicillin/streptomycin, 25ngml
 1 cholera toxin,
10ngml
 1 epidermal growth factor (Gibco), 5pM phosphoethanol-
amine, 10pgml
 1 hydrocortisone (Sigma, Taufkirchen, Germany),
and Insulin-Transferrin-Selenium (Gibco). Normal prostate
epithelial cells (PrECs) were cultured in Clonetics PrEGM basal
medium with supplements recommended by the supplier (Lonza,
Verviers, Belgium).
RNA preparation and quantitative RT–PCR
Total mRNA was isolated from cell cultures grown to 80%
confluence by the RNeasy Mini Kit (Qiagen, Hilden, Germany). For
tissues, the same kit was used following guanidinium/acid phenol/
chloroform extraction (peqGOLD TriFast, PeqLab, Erlangen,
Germany). After photometric quantification, 2mg mRNA was
transcribed into first-strand cDNA using SuperscriptII (Invitrogen,
Karlsruhe, Germany) with oligo-dT primers according to the
manufacturer’s protocol. Real-time PCR assays were carried out
by commercially available validated primer assays according to
the manufacturer’s protocol (Applied Biosystems, Weiterstadt,
Germany) using the ABI Prism 7900HT real-time PCR system.
To assess hTR levels, random primers were used in the reverse
transcription procedure and RT–PCR was conducted with the
primers 50-TTCAGCGGGCGGAAAAG-30,5 0-ACTCGCTCCGTTCCT
CTTCCT-30, and the labelled probe 50-6FAM-CCTTCCACCGTTCA
TTCTAGAGCAAACAA-TMR-30 (TIB MOLBIOL, Berlin, Germany).
Expression values for specific genes were related to those for TBP,
the most stable housekeeping gene during prostate carcinogenesis
(Schmidt et al, 2006).
DKC1 knockdown using RNA interference
Prostate cancer cell lines, 22Rv1 and Du145, were grown in
standard conditions and transfected using validated siRNA specific
for DKC1 mRNA (Invitrogen) at 20nM with Lipofectamine
RNAiMAX. A general nontargeting siRNA (Qiagen) was used as
a control at the same final concentration.
Viability, apoptosis, and senescence assays
Cell numbers were determined by the CellTiter-Glo luminescent
cell viability assay (Promega, Mannheim, Germany). Apoptosis
was followed using the Caspase-Glo 3/7 assay by the same
company according to the manufacturer’s instructions. For
senescence-associated b-galactosidase (SA-b-Gal) staining, cells
were washed in phosphate-buffered saline (PBS) and fixed in 3%
formaldehyde at room temperature for 3min. Staining for enzyme
activity was then performed by a standard procedure (Dimri et al,
1995) with LNCaP cells induced to become senescent by down-
regulation of the Snail transcription factor as a positive control.
DNA extraction and gene copy number determination
High-molecular-weight genomic DNA from tissue and cell lines
was isolated using the blood and cell culture DNA kit (Qiagen) as
described. Commercially available SNP genotyping assays (Applied
Biosystems) were adapted for use in quantitative real-time PCR to
measure gene copy numbers in 45 prostate cancer tissues as
described (Wlazlinski et al, 2007). For DKC1, SNP rs3752356 was
selected, of which essentially one allele is present in the German
population. TOP2B (rs11129202) at chromosome 3p was used as
a reference gene; two cases with low values in the TOP2B
measurement, likely because of allele loss, were excluded.
Duplicate analyses were carried out for each gene and sample
using 10ng of genomic DNA in an ABI Prism 7300 instrument with
detection of FAM and VIC fluorescence labels. The DCt method
was used for calculation of relative dosage. The average values
from four benign prostate tissue DNA samples in each experiment
were used as a standard and set as a gene dosage of 2 for TOP2B
and 1 for DKC1.
Western blot analysis
Total cellular protein extracts in RIPA buffer (5mg) or nuclear
proteins prepared using a commercially available nuclear extraction
kit (Active Motif, Carlsbad, CA, USA) were electrophoresed through
a 10% SDS–polyacrylamide gel and electroblotted onto immobilon-
P membranes (Millipore, Schwalbach, Germany). Nonspecific
binding was blocked by incubating the membrane in 5% non-fat
milk powder in PBS. Thereafter, membranes were incubated
overnight with rabbit polyclonal anti-dyskerin antibody (1:3000,
Atlas Antibodies, Stockholm, Sweden) and mouse monoclonal anti-
TBP (1:2000; Abcam, Cambridge, UK) as a loading control at 41C.
After washing, blots were incubated with HRP-conjugated anti-
rabbit or anti-mouse secondary antibody (1:100000, Santa Cruz,
Heidelberg, Germany) for 1h, followed by chemoluminescence
detection using the ECL advanced kit and exposure to Hyperfilms
(Amersham-Pharmacia, Munich, Germany).
Immunohistochemistry
Immunohistochemical detection of dyskerin in paraffin-embedded
tissues was established using biopsy specimens of human cervix
uteri as a positive control. To analyse the expression in human
prostate tissues, a tissue microarray comprising 24 prostate tissue
cores (12 carcinomas, 12 benign prostate tissue samples), as well as
three tissue cores of normal placenta, normal lymph node, and
normal thyroid gland, respectively, was generated (core diameters:
2mm each). Paraffin sections were treated with xylene and
ethanol. Sections were rehydrated and endogenous peroxidase
activity was eliminated by H2O2. After antigen retrieval, using
EDTA (pH 9) in a pressure cooker, endogenous biotin was
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at a 1:50 dilution for 1h at room temperature and subsequently
subjected to the EnVision detection system (Dako, Hamburg,
Germany). Reaction products were visualised by immersing slides
in diaminobenzidine tetrachloride.
Statistical methods
Statistical calculations were carried out using SPSS 12.0 (SPSS Inc.,
Munich, Germany).
RESULTS
Expression of DKC1 was first studied by real-time RT–PCR in a
series of 47 M0 prostate carcinomas and 13 benign prostate tissues
from prostatectomies (Figure 1A). In the carcinoma tissues, DKC1
mRNA was highly significantly elevated (t-test: Po0.001) compared
with benign tissues. The increase was significantly stronger in
higher-stage cancers (t-test: P¼0.031) and in cases with lymph node
metastases (t-test: P¼0.019). Moreover, expression of DKC1 was
significantly elevated in cases with recurrences (t-test: P¼0.030).
Kaplan–Meier analysis revealed a marked, but not significant (log-
rank: P¼0.140), difference in the clinical course between tumours,
with DKC1 expression above vs below median (Figure 1B).
The expression of the RNA subunit of telomerase, hTR, was
similarly, on an average, higher in cancer tissues than in benign
samples (Figure 2A), but the difference did not reach statistical
significance (t-test: P¼0.255). Cases with higher hTR expression
tended towards earlier recurrence (Figure 2B), but the difference
was not statistically significant according to Kaplan–Meier
analysis (log-rank: P¼0.094). In line with previous reports
(Bettendorf et al, 2003; Kamradt et al, 2003), no associations with
histopathological parameters were observed. Expressions of DKC1
mRNA and hTR were moderately well correlated with each other
(Spearman’s r: 0.360, P¼0.013).
To determine whether increased DKC1 expression reflects
increased tumour proliferation, its relationship to the expression
of the proliferation markers MKI67 (encoding the Ki67 protein)
and PCNA was determined. A moderate and significant correlation
was observed between DKC1 and MKI67 mRNA levels (Spearman’s
r: 0.353, P¼0.015), but none with PCNA mRNA. Thus, differential
levels of DKC1 mRNA in prostate cancer tissues are related to
differences in cell proliferation, but not closely so.
As the DKC1 gene is located at Xq28 and gain of X-chromosome
sequences is often observed in advanced stage prostate cancers, the
gene copy number was investigated by quantitative PCR in 45
cancer specimens (see Materials and Methods). Of these, 43 yielded
gene copy numbers of 0.4–1.5, with the average of normal tissues
set as 1. Two samples showed copy numbers between 2 and 2.5.
No significant correlation was observed between DKC1 gene copy
numbers and mRNA expression (Pearson’s r¼0.125). Thus, in
primary prostate cancers, gain of Xq28 does not seem to represent
a major factor responsible for DKC1 overexpression.
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Figure 1 DKC1 expression in prostate cancers. (A) RT–PCR quantita-
tion of expression in prostate carcinoma (T) and benign (N) tissues.
(B) Kaplan–Meier analysis of the effect of DKC1 expression on prostate
cancer biochemical recurrence. Top curve: below median expression;
bottom curve: above median expression.
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Figure 2 hTR expression in prostate cancers. (A) RT–PCR quantitation
of hTR expression in prostate carcinoma (T) and benign (N) tissues.
(B) Kaplan–Meier analysis of the effect of hTR expression on prostate
cancer recurrence. Top curve: below median expression; bottom curve:
above median expression.
Dyskerin in prostate cancer
P Sieron et al
1412
British Journal of Cancer (2009) 101(8), 1410–1416 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTo investigate possible functional consequences of DKC1 over-
expression, we used a siRNA-based approach in prostate cancer
cell lines. In cancer cells, as in tissues, DKC1 mRNA and protein
expression surpassed that in cultured normal PrECs (Figure 3).
Treatment of 22Rv1 and Du145 prostate carcinoma cell lines with
either one of three previously published DKC1 siRNAs (Montanaro
et al, 2006) for 3 days diminished DKC1 mRNA levels by 90–95%
compared with cells treated with a control siRNA. At this time
point, a strong loss of the protein was observed in Du145 cells,
whereas the protein level decreased only moderately in the 22Rv1
cell line (Figure 4). It is noteworthy that the antibody used in these
experiments reacted with a number of apparently unrelated
proteins in total cell extracts, whereas with nuclear extracts,
essentially only a single strong protein band was apparent.
After 3 days of treatment with siRNA directed against DKC1, cell
numbers – as measured by overall ATP levels – were moderately
decreased in the 22Rv1 line, but not significantly in Du145 cells
(Figure 4B). At this time point, no significant increase in apoptosis
was observed. An assay for active caspase 3/7 yielded values
of 3877±211 and 6086±1178 for 22Rv1 cells treated with DKC1
siRNA and control siRNA, respectively, and of 1239±110 and
1310±134, respectively, for Du145 cells. A more dramatic effect
was exerted by long-term DKC1 knockdown. Du145 or 22Rv1 cells
were treated with specific DKC1 siRNA or with control siRNA for
3 days and then passaged at the usual ratio. After 1 day of recovery,
siRNA treatment was repeated and cells were passaged again
3 days later. After the third passage (that is, 10 days in all), cells
treated with control siRNA were still proliferating and the cell
density was only slightly lower than that in untreated cells, whereas
only a few cells treated with siRNA against DKC1 survived
(Figure 5). Notably, cells treated with DKC1 siRNA neither
exhibited morphological signs of senescence nor stained positively
for the senescence marker, SA-b-Gal (Figure 5B). Instead, the main
effect on 22Rv1 cells was that they became diminutive, with an
elongated shape and often several thin extensions, and reattached
poorly to the cell culture dish after passaging (Figure 5B). In the
Du145 line, lack of adhesion was the major factor leading to cell
loss. Also, after 10 d treatment, occasional apoptotic cells became
morphologically evident in this cell line. However, the cell
numbers at that time were too low for quantitative determination
of the extent of apoptosis.
To investigate the reported anti-apoptotic effect of dyskerin
(Yoon et al, 2006) in prostate cancer cells, Du145 or 22Rv1 cells
pretreated with siRNA for 3 days were challenged with apoptosis
inducers TNF-a or tunicamycin (Shiraishi et al, 2005). The
particular proapoptotic agents were chosen, because death
receptor ligands such as TNF-a and endoplasmic reticulum stress,
through which tunicamycin acts, are thought to be particularly
important in prostate cancer. When caspase 3/7 activity was
determined as an indicator of apoptosis 24h later, no significant
differences were observed between Du145 cells treated with DKC1
siRNA or with a nontargeting control siRNA, whereas caspase
activity was rather diminished than enhanced by DKC1 knock-
down in 22Rv1 cells treated with either inducer of apoptosis
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Figure 3 Expression of DKC1 in prostate cancer cell lines.
(A) Expression of DKC1 relative to the reference gene TBP in the
indicated prostate cancer cell lines and normal prostate epithelial cells
(PrECs), according to quantitative RT–PCR. DKC1 and TBP were each
measured in triplicate, s.e.m. are indicated. (B) Western blot analysis of the
dyskerin protein in nuclear extracts of the indicated prostate cell lines and
normal PrECs. Equal amounts of nuclear extract from each cell line were
loaded and analysed for dyskerin as described in Materials and Methods.
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proapoptotic agent described above.
To verify that increased DKC1 mRNA expression in prostate
cancer results in increased protein levels, immunohistochemical
analyses for dyskerin were carried out on paraffin-embedded
tissues (Supplementary Figure 1). Optimal staining conditions
were established using biopsy specimens of human cervix uteri as
a positive control. In these, dyskerin was found to be strongly
expressed in nucleoli of both squamous and cylindrical epithelial
cells, although in a focal manner. Next, we investigated dyskerin
expression in 24 prostate tissue samples on a tissue microarray
with 12 matched tissue cores of prostate cancer and the respective
normal counterparts. We observed unspecific moderate-to-strong
immunohistochemical staining in the cytoplasm of both cancerous
and normal prostatic glands, but could not detect a specific
nucleolar dyskerin expression. To exclude heterogeneous expres-
sion in tissues as a source of this failure, dyskerin expression was
further investigated in large prostate cancer tissue sections from
Anti-DKC1
C
C
LN+
DKC
DKC
DKC IR
IR
IR
Control Anti-DKC1
22Rv1 Du145
Control
Figure 5 Effect of sustained DKC1 siRNA treatment on cell proliferation and survival. (A) Giemsa staining of culture dishes of the indicated cell lines after
10 days of treatment with siRNA directed against DKC1 or a nontargeting siRNA (control). (B) Morphology of 22Rv1 cells after treatment with DKC1
siRNA (DKC), control siRNA (IR), or mock treated (C) after 6 days (top row) or 10 days (centre row). Bottom row: results of staining for SA-b-Gal activity
in 22Rv1 cells treated for 6 days with DKC1 siRNA (DKC) or control siRNA (IR). Individual cells staining positively under either condition are indicated by
arrowheads in both panels. LNþ is a positive control of LNCaP cells induced to senescence by downregulation of the Snail transcription factor (WA Schulz
et al, unpublished observation).
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stwo patients. Indeed, in one of these samples, we found a few
tumour cells with a strong nucleolar dyskerin expression, whereas
the vast majority of tumour cells, as well as all other cells,
remained negative. From these observations we conclude that the
commercially available antibody is not sensitive enough to allow a
systematic analysis of dyskerin expression in paraffin-embedded
prostatic tissues.
DISCUSSION
Our data indicate that DKC1 overexpression is common in
prostate cancer, and is associated with adverse histopathological
features, especially tumour extension. These data fit excellently
with those reported by others for breast cancer (Montanaro
et al, 2006, 2008a), suggesting that overexpression of DKC1 might
be a frequent property of aggressive carcinomas. It is note-
worthy that we observed only a weak-to-moderate association
between DKC1 levels and actual markers of tumour proliferation,
such as MKI67 and PCNA, suggesting that the increase in
DKC1 expression is not simply a by-product of enhanced cell
proliferation.
Dyskerin functions in several cellular processes, such as
pseudouridine formation and consequently RNA and general
protein biosynthesis (Filipowicz and Pogacic, 2002), biosynthesis
of hTR, and stabilisation of the telomerase complex (Chang et al,
2002; Cohen et al, 2007), as well as regulation of apoptosis (Yoon
et al, 2006). Downregulation of dyskerin by siRNA in prostate
cancer cells did not elicit apoptosis by itself or sensitise to
induction of apoptosis by TNF-a or tunicamycin, agents chosen
because of their relevance to prostate cancer (Shiraishi et al, 2005).
In fact, in the 22Rv1 cell line, activation of caspase 3/7 by these
agents seemed rather muted by the downregulation of dyskerin. As
growth of 22Rv1 was more rapidly affected by DKC1 knockdown
than that of Du145, it is possible that this surprising effect may be
a consequence of already diminished protein biosynthetic capacity
in this cell line.
Neither were morphological signs of senescence nor increased
expression of the senescence marker SA-b-Gal induced by DKC1
siRNA, which would be expected if loss of telomerase function was
the primary effect of dyskerin downregulation in these cells.
Complete cessation of cell growth and proliferation was observed
after at most three passages, corresponding to 10 days of
treatment. By comparison, inhibition of hTERT by a dominant-
negative protein arrests the proliferation of prostate cancer cell
lines only after several weeks (Guo et al, 2001).
Thus, the most critical function of dyskerin in prostate
cancer cells seems to lie in its role in protein biosynthesis. The
phenotype elicited by DKC1 siRNA, that is, a gradual cessation of
proliferation, decreased cell size, and inability to reattach after
trypsinisation or even spontaneous detachment, is fully compatible
with a defect in protein biosynthesis. In keeping with this
interpretation, in breast cancer cells, a close correlation between
pseudouridine levels and DKC1 expression has been directly
demonstrated (Montanaro et al, 2006). Therefore, in breast as
well as prostate cancers, overexpression of dyskerin may be a
primary necessity to support the increased RNA and protein
biosynthesis of cancer cells. In addition, the observation that DKC1
mRNA expression in prostate cancer tissues correlated, if only
moderately, with hTR levels supports the idea that for the long-
term growth of tumours in vivo, dyskerin may additionally be
important to maintain telomerase activity. The same conclusion
has recently been reached for breast cancers (Montanaro et al,
2008a).
It remains to be demonstrated that the increased levels of DKC1
mRNA in prostate cancer tissues result in an overexpression of the
protein, as was shown for breast cancer (Montanaro et al, 2006).
Moreover, in view of the association of increased DKC1 mRNA
with prostate cancer stage and a tendency towards association with
recurrence, it seems highly desirable to explore the prognostic
value of dyskerin expression using tissue microarrays. Unfortu-
nately, we could not perform a systematic analysis in paraffin-
embedded benign or cancerous prostate cancer tissues from
archival samples, as the commercial polyclonal antibody success-
fully used in western blotting with nuclear extracts (Figures 3 and
4) detected nucleolar dyskerin expression in a subset of normal
uterine cervical cells, but only in very few prostate cancer cells, and
the polyclonal antibody used on breast cancers (Montanaro et al,
2006) is depleted. Therefore, this analysis has to be postponed until
an appropriate antibody is available.
At first glance, the finding that DKC1 is overexpressed in
common carcinomas seems somewhat paradoxical, given that
dyskerin-inactivating mutations in dyskeratosis congenita predis-
pose to cancer development, and DKC1 is downregulated in
sporadic CLL (Poncet et al, 2008). Moreover, a complete lack of
dyskerin function is lethal. It seems, though, that the mutant
proteins in dyskeratosis congenita retain pseudouridine synthase
activity, but by failing to stabilise telomerase, impair long-term cell
proliferation and elicit activation of checkpoints (Gu et al, 2008).
In these circumstances, cells with mutations allowing proliferation
in the absence of functional telomeres and regardless of checkpoint
activation would possess a huge selective advantage, which
ultimately leads to cancer. According to this argument, in tumours
arising in dyskeratosis congenita, dyskerin mutations would
constitute the primary event and favour the development of
secondary changes that initiate cancer development. Conversely, in
the progression of breast and prostate carcinomas, dyskerin
overexpression may represent a secondary change necessary to
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smeet the requirements for increased RNA biosynthesis and
telomerase activity.
The precise mechanisms leading to overexpression of dyskerin
in common carcinomas remain to be elucidated in further studies.
As we did not observe increased gene copy numbers in prostate
cancers with DKC1 overexpression, they are likely epigenetic. In
this respect, it could be significant that DKC1 was recently
identified as a direct target of MYC (Alawi and Lee, 2007), a major
regulator of cancer cell growth frequently overexpressed in
aggressive breast and prostate cancers.
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